Breaking News, Collaborations & Alliances

BioMed X France Launches First Research Team on Servier’s R&D Campus

The team is called Team ADB, for “AI-Empowered Design of Bispecific Antibodies.”

Author Image

By: Patrick Lavery

Content Marketing Editor

BioMed X has launched its first research team in France, at the XSeed Labs incubator on Servier’s R&D campus. This location, at Paris-Saclay University, is hosted at the Spartners facility operated jointly by Servier and BioLabs.

The research team’s name, Team ADB, stands for “AI-Empowered Design of Bispecific Antibodies.” BioMed X says it helps the company establish a presence in one of the fastest-growing life science ecosystems in Europe.

France Research Team’s Leader

Tomabu Adjobimey, PhD, leads the research team. He is Associate Professor of Immunology and Microbiology at the University of Abomey-Calavi in Benin.

“Our goal is to develop an AI-driven platform that integrates structural modeling, machine learning, and experimental validation,” Adjobimey said. “By enabling more predictive and structure-aware antibody engineering, this approach could significantly accelerate the discovery of innovative biologic therapeutics.”

Adjobimey will get assistance from Paula Wagner Egea, PhD, BioMed X France Managing Director and Site Head.

“This XSeed Labs team represents an important milestone for BioMed X as we establish our presence in France,” she said. “We are creating a unique environment for interdisciplinary innovation at the intersection of artificial intelligence and biomedical research. With Team ADB and our partners at Servier, we are bringing fresh thinking to one of the most exciting frontiers.”

BioMed X and Servier See Promise

To that end, BioMed X and Servier claim bispecific antibodies represent one of the most promising classes of biologic therapeutics. As they can engage two molecular targets simultaneously, they hold potential for new treatment strategies in oncology and immunology.

It will now be the research team’s task to tackle bispecific antibodies’ engineering challenges. These include structural constraints and the limited predictability of dual-target interactions.

Ultimately, however, the goals for these therapeutics are reliable stability, specificity, and manufacturability.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters